SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Repros Therapeutics (Nasdaq: RPRX) $3.50, Up $1.00. Today announced it has completed two animal model studies of the use of Proellex in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company. Most importantly, extrapolating the data from the exposure seen in animals to that seen in humans, administration of Proellex via the vaginal route may achieve maximum circulating concentrations that are approximately 2% of that exhibited in humans at the 50 mg dose and only 6.5% of the lowest oral dose, 12.5 mg, previously tested in humans.
The Company believes the high concentrations of the active ingredient and its primary metabolite attained in first pass absorption and processing by the liver resulted in the delayed toxicity exhibited in roughly 3-4% of the women administered the 50 mg dose of the drug in Phase III studies. At 12.5 mg there were no adverse liver toxicity signals different than placebo. The maximum concentrations of parent and metabolite for the 12.5 mg dose were 25% of the 50 mg dose.
What They Do: Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
IncrediMail Ltd (Nasdaq: MAIL) Trading at $7.60, Up $0.50. Today announced that it has signed a new 2 year agreement with Google. The new agreement is effective January 1, 2011.
Commenting on the agreement, Mr. Josef Mandelbaum, IncrediMail’s CEO, said, “We are very pleased and proud to extend our collaboration with Google, the global search market leader. The new agreement provides the basis for a more extended relationship and I am looking forward to working closely with Google to grow our existing business with them and to find other areas of cooperation that will further strengthen our partnership.”
What They Do: IncrediMail Ltd. is a digital media company that builds, acquires and enhances downloadable consumer applications.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
